1.. Introduction {#S0001}
================

World health organization (WHO) declared global public health emergency due to the outbreak of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) from the city of Wuhan, China in December 2019; subsequently, so far 192 countries were affected over the world (Minah et al., [@CIT0038]). Coronaviruses (CoV) belongs to the family of enveloped positive-strand RNA viruses, in which SARS-CoV-2 are the β-coronavirus and has severe infectivity and transmissibility than SARS and MERS-CoVs (Su et al., [@CIT0044]; Zhu et al., [@CIT0053]; Tang et al., [@CIT0045]). Generally, the coronaviruses are the enveloped viruses, consist of structural proteins such as spike (S), membrane (M), envelope (E) and nucleocapsid (N) (Hossam et al., [@CIT0022]; Boopathi et al., [@CIT0008]). The S-spike protein of SARS-CoV-2 binds with the angiotensin-converting enzyme 2 (ACE2) with 10 fold more rapidly than SARS-CoV to facilitate further infection (Li-Sheng et al., [@CIT0036]). Further, viral mRNA translates the viral polyproteins (Elfiky, [@CIT0015]) and they are cleaved into functional polypeptides by SARS-CoV-2 main protease (M^pro^) which plays an important role in the development of new viruses. Hence, targeting M^pro^ and developing the potential inhibitor will help to control the disease progression. The SARS-CoV-2 M^pro^ acts as an attractive target and the structure of viral M^pro^ contains 306 amino acids with three major domains (I-III) and 11 cleavage sites for single polyprotein 1ab. The domains I and II form a deep cleft where the substrate binding site occurs and the catalytic dyad (His41 and Cys145) present in the centre of the site (Xiaoyu et al., [@CIT0049]; Linlin et al., [@CIT0035]). In addition, the substrate-binding site M^pro^ has conserved amino acids that are critical for pocket formation and they are common in all other CoVs including Leu27, His41, Tyr53, Phe139, Gly142, His163, Glu166, Leu167, His172, Asp187 and Gln192 (Fenghua et al., [@CIT0018]). Hence, to inhibit this viral protease, drugs should form strong interactions with the catalytic dyad and these conserved amino acids. To solve the drug crisis, the drug repurposing strategy is being adopted and it is functional in this global health emergency; the present work provides strong evidence for the drug activity and possible for drug repurposing. Currently, the anti-viral drugs lopinavir, ritonavir (HIV protease inhibition) and oseltamivir (influenza virus) are being used to treat the severe infected patients of COVID-19 (<https://www.the-scientist.com/news-opinion/flu-and-anti-hiv-drugs-show> efficacyagainstcoronavirus-67052; Muralidharan et al., [@CIT0039]; Elmezayen et al., [@CIT0016]; Khan et al., [@CIT0031]; Adeoye et al., [@CIT0002]). In this pandemic scenario, computational based identification of potential drug candidates against SARS-CoV-2 M^pro^ is contributing an essential role in drug designing in a short period of time (Al-Khafaji et al., [@CIT0003]). Hence, several studies including synthetic (Pant et al., [@CIT0041]; Joshi et al., [@CIT0030]; Das et al., [@CIT0012]; Lobo-Galo et al., [@CIT0037]) and plant derived (Aanouz et al., [@CIT0001]; Enmozhi et al., [@CIT0017]; Islam et al., [@CIT0027]; Wahedi et al., [@CIT0048]; Umesh et al., [@CIT0047]; Kumar et al., [@CIT0033]; Gyebi et al., [@CIT0021]) molecules are showing better inhibition against SARS-CoV-2 M^pro^. Also *in silico* and *in vitro* studies on HIV protease inhibitor nelfinavir shows that it exhibits remarkable inhibition activity against SARS-CoV and SARS-CoV-2 (Yamamoto et al., [@CIT0051]; Bolcato et al., [@CIT0007]; Yamamoto et al., [@CIT0050]). The molecules lopinavir, ritonavir and nelfinavir form strong interactions with the active site amino acids including Asp25 and Asp25′of HIV-1 protease enzyme (Lv et al., 2015). Similarly, these drugs also form strong interaction with the catalytic dyad His41, Cys145 and other active site residues of the SARS-CoV-2 (Bolcato et al., [@CIT0007]). Furthermore, studies on the inhibition mechanism of several inhibitors of the SARS-CoV M^pro^ (Bacha et al., [@CIT0005]; Chen et al., [@CIT0010]; Zhou et al., [@CIT0052]) have been reported to understand the binding mechanism of inhibitors. Several research groups actively involved in searching a potential drug from the approved/clinical trial drugs to use as the repurposed drugs and are in progress. In the present study, we have chosen two clinical trial drugs (inhibitors) of HIV-1 protease ([Scheme 1](#SCH0001){ref-type="scheme"}) to be used as the repurposed drug from the *in silico* study.

![Chemical structure of (a) TMB607 and (b) TMC310911 molecules.](TBSD_A_1786459_SCH0001_B){#SCH0001}

\(i\) un-boosted TMB607 (<https://clinicaltrials.gov/ct2/show/NCT03110549>) and (ii) TMC310911 boosted with ritonavir (<https://clinicaltrials.gov/ct2/show/NCT00838162>) shown in [Figure 1](#F0001){ref-type="fig"}.

![Molecular structure and the atom labelling of (a) TMB607 and (b) TMC310911.](TBSD_A_1786459_F0001_C){#F0001}

Reportedly, these two drugs were found to be safe and well-tolerated among the healthy volunteers with no-dose limiting toxicity (Stellbrink et al., 2014; Jinzi et al., [@CIT0029]). The molecular binding mechanism of these two drugs with SARS-CoV-2 M^pro^ enzyme is not yet known; to understand the same, here we have carried out the molecular docking, molecular dynamics (MD) simulations and binding free energy calculations. The detailed information about the stability, intermolecular interactions and binding affinity of these two drug molecules in the active site of the SARS-CoV-2 M^pro^ enzyme are provided from the molecular docking and MD simulations. These results are useful to evaluate the two clinical trial drugs to consider as the repurposed drugs for treatment of the devastating COVID-19 disease after *in vitro* and clinical studies. Furthermore, we also interested to understand the intermolecular interactions of TMB607 and TMC310911 with the catalytic dyad and conserved amino acids among seven coronaviruses reported in Fenghua et al. ([@CIT0018]), which will be helpful to identify the potential inhibitor.

2.. Materials and methods {#S0002}
=========================

2.1.. Ligand preparation and molecular docking {#S0002-S2001}
----------------------------------------------

The geometry of molecules TMC310911 and TMB607 were optimized with B3LYP/6-311G\*\* level of density functional theory (DFT) (Parr & Yang, [@CIT0042]) using *Gaussian03* software (Frisch et al., [@CIT0019]). The X-ray crystal structure of the SARS-CoV-2 M^pro^ (PDB: 6LU7) was retrieved from Protein Data Bank (PDB). The structure was optimized with OPLS_2005 force field using *protein preparation wizard* and the selected two molecules were prepared and optimized by the *Ligprep* routine of *Maestro* application incorporated in the *Schrödinger program* suit LLC (Jacobson et al., [@CIT0028]). Further, an induced fit docking (IFD) was carried out for these two compounds with the SARS-CoV-2 M^pro^. In the IFD, the standard protocol was chosen; the gird box was centred on the catalytic site residues. The van der Waals scaling of both ligands and protein was fixed at 0.5. Finally, the *extra precision* (XP) mode of IFD was performed. The intermolecular interactions and electrostatic potential map of both ligand-M^pro^ complexes were analyzed using *PyMol* (Delano, [@CIT0014]) and *Discovery studio visualizer* softwares (Dassault Systems BIOVIA, [@CIT0013]).

2.2.. MD Simulations and binding free energy {#S0002-S2002}
--------------------------------------------

The MD simulations of SARS-CoV-2 M^pro^, TMC310911-SARS-CoV-2 M^pro^ and TMB607-SARS-CoV-2 M^pro^ complexes were carried out using *Sander* routine of *AMBERTOOLS14* package (Case et al., [@CIT0009]) to understand the stability and the binding affinity of the two molecules in the substrate binding site of SARS-CoV-2 M^pro^ enzyme. The orthorhombic shell of TIP3P water box was generated with a minimum solute-wall at 8** **Å distance and to neutralize the charges of the complex system, 4 Na^+^ ions were added. Further, both complexes were minimized for the removal of steric clashes present in the complexes and annealed from 0 to 300** **K for 500ps time period and equilibrated at 300** **K for 500ps with the maintenance of canonical ensemble (NVT) (Glenn et al., [@CIT0020]). The MD production phase was initiated and continued to 50** **ns in 2fs time step at constant temperature (300** **K) and pressure (1** **bar) using *Langevin thermostat* and *Berendsen barostat* as in the heating process (Andrew & Ben, [@CIT0004]; Berendsen et al., [@CIT0006]). *VMD* (Humphrey et al., [@CIT0026]) and *CPPTRAJ* software (Daniel & Cheatham, [@CIT0011]) were used to analyze the MD trajectory. MM-GBSA calculation was carried out for both complexes based on the GB model (Onufriev et al., [@CIT0040]).

3.. Results and discussion {#S0003}
==========================

3.1.. Molecular docking and intermolecular interactions {#S0003-S2001}
-------------------------------------------------------

The glide energy of TMB607-SARS-CoV-2 M^pro^ and TMC310911-SARS-CoV-2 M^pro^ complexes obtained from the molecular docking simulation is −10.3 and −7.1** **kcal/mol, respectively. The intermolecular interactions of TMB607 and TMC310911 molecules with the SARS-CoV-2 M^pro^ enzyme were identified and presented in [Tables 1](#t0001){ref-type="table"} and [2](#t0002){ref-type="table"}. The H27 atom of molecule TMB607 forms hydrogen bonding interactions with one of the catalytic dyad amino acids Cys145 with a distance of 3.0** **Å. In addition, the molecule also forms π⋅⋅⋅π stacked type of hydrophobic interaction with the amino acid His41 at the distance of 4.2** **Å. And TMB607 also forms hydrogen bonding interaction with Glu166 at the distance of 3.4** **Å and alkyl···π-orbital type of hydrophobic interaction with His163 of catalytic dyad at the distance of 4.8** **Å, the conserved amino acids of M^pro^ enzyme. In contrast to TMB607, the molecule TMC310911 only forms alkyl···π-orbital type of interaction with the amino acid His41 at the distance of 4.9** **Å and hydrogen bonding interaction with the conserved amino acids Glu166 and Leu167 at the distance of 2.7 and 2.3** **Å, respectively. Further, to understand the conformation, stability of these intermolecular interactions and binding affinity of both drug molecules with the M^pro^ enzyme, the MD simulation has been performed.

###### 

Intermolecular interaction distances of TMB607···SARS-CoV-2 M^pro^ complex.

  TMB607··· SARS-CoV-2 M^pro^              Distance (Å)   
  ---------------------------------------- -------------- --------
  **Hydrogen bonding interactions**                       
  C24···NE2/His41                          4.0            2.8
  C33···O/Leu141                           3.2            --
  O6···HD21/HA/Asn142                      2.4, 2.6       --
  H27···SG/Cys145                          3.0            --
  O6···HB2/Cys145                          7.6            2.5
  H23···HN/Glu166                          3.4            --
  O5···HN/Glu166                           --             2.7
  O1···HE21/Gln189                         2.1            --
  O4···HE22/Gln189                         2.7            1.9
  H24, C6···O/Thr190                       2.5, -         -, 3.4
  O1···HN/Gln192                           --             1.9
  **Hydrophobic interactions**                            
  Ring II···His41 (π-π-stacked)            4.2            --
  Ring I···SD/Met49 (π-orbital···Sulfur)   4.9            5.3
  Ring I···SG/Cys145(π-orbital···Sulfur)   5.0            5.3
  C33···His163 (alkyl···π-orbital)         4.8            4.8
  C33···His172 (alkyl···π-orbital)         5.1            --

###### 

Intermolecular interaction distances of TMC310911···SARS-CoV-2 M^pro^ complex.

                                        Distance (Å)   
  ------------------------------------- -------------- -----
  **Hydrogen bonding interactions**                     
  S2···O/Phe140                         2.4            --
  H40···O/His164                        3.5            --
  H15···OE1/Glu166                      2.2            --
  H20···O/Glu166                        --             2.0
  S···OE2/Glu166                        3.5            --
  C17···O/Leu167                        3.4            --
  H45···O/Arg188                        \--            2.7
  C32···OE1/Gln189                      3.7            --
  **Electrostatic interaction**                        
  O6···OE2/Glu166 (Anion···π-orbital)   3.5            --
  **Hydrophobic interactions**                         
  Ring I···His41 (alkyl···π-orbital)    4.9            --
  Ring I···Met49 ( alkyl···π-orbital)   --             5.0
  C38···Met165 (alkyl···alkyl)          4.7            5.5
  C16···Pro168 (alkyl···alkyl)          4.3            4.2

3.2.. Evaluation of MD simulation and intermolecular interactions {#S0003-S2002}
-----------------------------------------------------------------

The MD simulations for the SARS-CoV-2 M^pro^ (apo-enzyme), TMB607-SARS-CoV-2 M^pro^ and TMC310911-SARS-CoV-2 M^pro^ complexes have been carried out for 50** **ns time period. [Figure 2](#F0002){ref-type="fig"} shows the RMSD and RMSF values of both complexes and are found to be stable over the 50** **ns simulations; in which the RMSD values of the TMB607-SARS-CoV-2 M^pro^ complex are less (∼1.4** **Å) than the TMC310911-SARS-CoV-2 M^pro^ complex (∼1.8** **Å) and SARS-CoV-2 M^pro^ (∼2.4** **Å) over the entire simulations; this confirms the high stability of TMB607-SARS-CoV-2 M^pro^ complex. Further, the RMSF values ([Figure 2b](#F0002){ref-type="fig"}) illustrate that the fluctuations of active site residues are found to be low for both complexes, in which notably, the RMSF values of TMB607-SARS-CoV-2 complex is lower than TMC310911-SARS-CoV-2 M^pro^ complex and SARS-CoV-2 M^pro^ ([Figure 2](#F0002){ref-type="fig"}). This difference reveals the strong interactions between TMB607 and the active site residues of SARS-CoV-2-M^pro^.

![(a) RMSD and (b) RMSF plots of apo-protein, TMB607 and TMC310911-SARS-CoV-2 M^pro^ complexes. \[Black: SARS-CoV-2 M^pro^; Red: TMB607-SARS-CoV-2 M^pro^; Blue: TMC310911-SARS-CoV-2 M^pro^ complexes.\].](TBSD_A_1786459_F0002_C){#F0002}

The intermolecular interactions of the molecules TMC310911 and TMB607 with the neighbouring amino acids present in the active site of SARS-CoV-2 M^pro^ during the MD simulation are listed in [Tables 1](#t0001){ref-type="table"} and [2](#t0002){ref-type="table"} respectively. The hydrogen bonding interactions of the complexes obtained from the docking and MD simulations are shown in [Figure 3(a](#F0003){ref-type="fig"} and [b)](#F0003){ref-type="fig"}.

![Intermolecular interactions of (a) TMB607-SARS-CoV-2 M^pro^ and (b) TMC310911-SARS-CoV-2 M^pro^ complexes obtained from docking and the MD simulations.](TBSD_A_1786459_F0003_C){#F0003}

It is found that at the 50** **ns MD simulation, the molecule TMB-607 forms strong interactions with the amino acids His41 and Cys145 of catalytic dyad, which is stronger than the same found in docked complex and the corresponding hydrogen bonding interaction distances are 2.8 and 2.5** **Å, respectively. Further, the molecule also forms strong hydrogen bonding interaction with the conserved amino acids including Glu166, Gln189 and Gln192 at the distance of 2.7, 1.9 and 1.9** **Å, and alkyl⋅⋅⋅π-orbital type of hydrophobic interaction with the residue His163 at the distance of 4.8** **Å, respectively. Interestingly, these interactions are in correlation with the recently reported inhibitor α-ketomide (Linlin et al., [@CIT0035]). The intermolecular interaction of TMB607 molecule with the M^pro^ enzyme are compared with some of the reported SARS-CoV M^pro^ enzyme inhibitors (Bacha et al., [@CIT0005]; Chen et al., [@CIT0010]; Zhou et al., [@CIT0052]) and HIV protease as well as SARS-CoV-2 M^pro^ inhibitors including lopinavir, ritonavir and nelfinavir (Lv et al., [@CIT1423917]; Bolcato et al., [@CIT0007]). The corresponding interactions are compared in [Table 3](#t0003){ref-type="table"} and the results indicate that how the molecule TMB607 is potentially interact with SARS-CoV-2 M^pro^ enzyme.

###### 

List of catalytic dyad and conserved amino acids of SARS-CoV and SARS-CoV-2 M^pro^ interacting with various inhibitors.

  Catalytic dyad & Conserved amino acids of M^pro^   SARS-CoV-2 M^pro^   SARS-CoV M^pro^                                                
  -------------------------------------------------- ------------------- ----------------- -------- -------- -------- -------- -------- --------
  His41                                              His41               --                His41    His41    His41    His41    His41    His41
  Cys145                                             Cys145              --                --       Cys145   Cys145   Cys145   Cys145   Cys145
  Leu27                                              --                  --                --       --       --       --       --       --
  Tyr53                                              --                  --                --       --       --       --       --       --
  Phe139                                             --                  --                --       --       --       --       --       --
  Gly142                                             --                  --                --       --       --       --       --       --
  His163                                             His163              --                --       --       --       His163   --       --
  Glu166                                             Glu166              Glu166            Glu166   Glu166   Glu166   Glu166   --       --
  Leu167                                             Leu167              --                Leu167   --       --       --       --       --
  His172                                             His172              --                --       --       --       His172   --       --
  Asp187                                             --                  --                Asp187   --       --       --       --       --
  Gln192                                             Gln192              --                --       --       --       --       --       --

Intermolecular interactions of TMC310911-SARS-CoV-2 M^pro^ complex is shown in [Figure 3](#F0003){ref-type="fig"}. In this complex, it is found that except with Glu166, the molecule does not form any strong interaction with the conserved amino acids present in the active site of SARS-CoV-2 M^pro^. Furthermore, the Connolly surface representation and intermolecular interactions ([Figure 3b](#F0003){ref-type="fig"}) indicate that this molecule was unable to cover the substrate-binding site during the MD simulation; hence, the molecule is found to be less stable in the active site. These modifications can be well understood from the Connolly surface representation, which displays the position of the ligands in the active site ([Figure 4](#F0004){ref-type="fig"}).

![Connolly representation of (a) TMB607-SARS-CoV-2 M^pro^ and (b) TMC310911-SARS-CoV-2 M^pro^ complexes obtained from docking and MD simulations.](TBSD_A_1786459_F0004_C){#F0004}

3.3.. Binding free energy {#S0003-S2003}
-------------------------

The MM-GBSA, MM-PBSA and decomposition free energy values of TMB607-SARS-CoV-2 M^pro^ and TMC310911-SARS-CoV-2 M^pro^ complexes were calculated from the MD trajectories. The MM-GBSA free energy values of both complexes are −43.7 and −34.9** **kcal/mol, respectively. Contributions of various energy components to the binding free energy for TMB607 and TMC310911 with SARS-CoV-2 M^pro^ of both complexes are listed in [Table 4](#t0004){ref-type="table"}.

###### 

Contributions of various energy components to the binding free energy (kcal/mol) for TMB607-SARS-CoV-2 M^pro^ and TMC310911-SARS-CoV-2 M^pro^ complexes.

  Energy components                     TMB607   TMC310911
  ------------------------------------- -------- -----------
  $\Delta E_{\mathit{vdw}}$             −60.4    −46.6
  $\Delta E_{\mathit{electrostatic}}$   −31.1    −12.1
  $\Delta G_{PB/GB}$                    51.8     −28.9
  $\Delta E_{SA}$                       −7.7     −5.1
  $\Delta E_{\mathit{gas}}$             −87.8    −58.7
  $\Delta G_{\mathit{sol}}$             44.1     23.8
  $\Delta G_{\mathit{Total}}$           −43.7    −34.9

The decomposition free energy values of these two complexes are plotted in [Figure 5](#F0005){ref-type="fig"}. In concurrence with the results of intermolecular interactions, the TMB607 molecule contributes low decomposition free energy with the catalytic dyad amino acids His41 (−1.4** **kcal/mol) and Cys145 (−1.9** **kcal/mol) and conserved residues including Leu167 (−1.3** **kcal/mol), Gln189 (−4.4** **kcal/mol) and Gln192 (−1.6** **kcal/mol), respectively. The decomposition free energy contribution of the molecule TMC310911 with the conserved residues is quite higher than TMB607. The molecule has low binding energy contribution with the conserved amino acids Leu167 (−1.9** **kcal/mol) and Gln189 (−0.97** **kcal/mol). Hence, the interaction between TMB607 molecule and the active site residues (His41, Met49, Cys145, Glu189, Ala191 and Gln192) contribute for the low binding energy of TMB607-SARS-CoV-2 M^pro^ complex. Whereas in TMC310911-SARS-CoV-2 M^pro^ complex, only four amino acids (Met165, Leu167, Pro168 and Ala191) are contributing, the binding energy is higher than TMB607.

![Decomposition free energy plots of (a) TMB607-SARS-CoV-2 M^pro^ and (b) TMC310911-SARS-CoV-2 M^pro^ complexes during the MD simulations.](TBSD_A_1786459_F0005_C){#F0005}

4.. Conclusion {#S0004}
==============

Currently, the HIV-1 protease inhibitor combinations are being used to treat severely infected COVID-19 patients successfully. Besides this, several laboratories are involved in the preparation of repurposed drugs from the approved/clinical trial drugs. In the present study, we have chosen two clinical trial HIV-1 protease inhibitors TMB607 and TMC310911 and performed molecular docking, MD simulation and binding free energy calculations. The docking analysis shows that the molecule TMB607 forms strong interactions with the catalytic dyad residues His41 and Cys145. Further, the RMSD and RMSF values of TMB607-SARS-CoV-2 M^pro^ complex are found to be low on comparing with TMC310911-SARS-CoV-2 M^pro^. During the MD simulation, the molecule TMB607 maintains the strong intermolecular interactions with the catalytic dyad residues His41, Cys145 and the conserved amino acid residues including Glu166, Gln189 and Gln192, which plays a crucial role in proteolytic process. Whereas, the molecule TMC310911 forms strong interaction with the conserved residue Glu166 alone and this molecule also exhibits less stability in the active site of SARS-CoV-2 M^pro^. The MM-GBSA and decomposition binding free energy analysis also confirm that the molecule TMB607 strongly binds with the SARS-CoV-2 M^pro^. Hence, from the present *in silico* study, we conclude that the molecule TMB607 (unboosted with ritonavir) acts as a standalone drug, will be the promising candidate to inhibit the SARS-CoV-2 M^pro^, it may be considered as a repurposed drug to treat the devastating COVID-19 viral disease after in vitro and clinical studies. The results also provide key information useful for further drug designing.
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